pd168393 has been researched along with Disease Models, Animal in 6 studies
PD 168393 : A member of the class of quinazolines carrying bromoanilino and acrylamido substituents at positions 4 and 6 respectively.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PD168393 was used to inhibit EGFR signaling activation." | 1.40 | Epidermal growth factor receptor inhibitor ameliorates excessive astrogliosis and improves the regeneration microenvironment and functional recovery in adult rats following spinal cord injury. ( Li, JJ; Li, ZW; Mao, XQ; Shi, GF; Wang, F; Wang, L; Wang, Q; Wu, JJ; Zhang, JP; Zou, J, 2014) |
| "PD168393, an EGFRI, was applied topically to the ear skin of mice with or without mast cell deficiency." | 1.37 | Phenylbutyrate suppresses distinct skin reactions that are enhanced by blockade of epidermal growth factor receptor signaling. ( Chung, YL; Pui, NN, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Hsieh, TF | 1 |
| Chen, CC | 1 |
| Ma, WL | 1 |
| Chuang, WM | 1 |
| Hung, XF | 1 |
| Tsai, YR | 1 |
| Lin, MH | 1 |
| Zhang, Q | 1 |
| Zhang, C | 1 |
| Chang, C | 1 |
| Shyr, CR | 1 |
| Li, ZW | 1 |
| Li, JJ | 1 |
| Wang, L | 1 |
| Zhang, JP | 1 |
| Wu, JJ | 1 |
| Mao, XQ | 1 |
| Shi, GF | 1 |
| Wang, Q | 1 |
| Wang, F | 1 |
| Zou, J | 1 |
| Zhang, S | 1 |
| Ju, P | 1 |
| Tjandra, E | 1 |
| Yeap, Y | 1 |
| Owlanj, H | 1 |
| Feng, Z | 1 |
| Chung, YL | 1 |
| Pui, NN | 1 |
| Erschbamer, M | 1 |
| Pernold, K | 1 |
| Olson, L | 1 |
6 other studies available for pd168393 and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation.
Topics: Androgens; Animals; Butylhydroxybutylnitrosamine; Carcinogenesis; Castration; Disease Models, Animal | 2013 |
Epidermal growth factor receptor inhibitor ameliorates excessive astrogliosis and improves the regeneration microenvironment and functional recovery in adult rats following spinal cord injury.
Topics: Animals; Animals, Newborn; Astrocytes; Cells, Cultured; Disease Models, Animal; ErbB Receptors; Expl | 2014 |
Inhibition of Epidermal Growth Factor Receptor Improves Myelination and Attenuates Tissue Damage of Spinal Cord Injury.
Topics: Animals; Astrocytes; Axons; Disease Models, Animal; ErbB Receptors; Female; Mice; Myelin Sheath; Neu | 2016 |
Phenylbutyrate suppresses distinct skin reactions that are enhanced by blockade of epidermal growth factor receptor signaling.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Cells, Cultured; Chemokine CCL2; Derma | 2011 |
Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; ErbB Receptors; Female; In | 2007 |